So basically, DCF valuation is looking into the companies predicted future cash flow (by using revenue, net income and margin figures) and discounting it back to the present day value to determine the fair price you should pay for it. For me, this is the more reliable valuation method.
The intrinsic valuation method (note: I may not be using the right "term") is simply using the revenue growth rate to determine future EPS (say in about 5 years time) and using the average PE ratio, to determine the price of the equity in 5 years time. So, Future price in 5 years = EPS (in 5 years) X PE (which gives you a price target). The value you get, halve it to compensate for any errors/assumptions, and then you can also apply a Margin of safety. Again, the 2nd valuation is much more less reliable in comparison to the first method, but it gives a quick/rough figure.
You can also apply the Dividend Discount valuation method here (which i am yet to do) since the company pays a stable, growing dividend.
Hope that helps.
- Forums
- ASX - By Stock
- WHY NO LOVE?
So basically, DCF valuation is looking into the companies...
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SSM (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.53 |
Change
0.010(0.66%) |
Mkt cap ! $942.4M |
Open | High | Low | Value | Volume |
$1.51 | $1.54 | $1.51 | $12.68M | 8.320M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10126 | $1.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.54 | 10126 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 10126 | 1.520 |
2 | 10784 | 1.515 |
1 | 5000 | 1.500 |
1 | 6734 | 1.485 |
1 | 2027 | 1.480 |
Price($) | Vol. | No. |
---|---|---|
1.535 | 10126 | 1 |
1.540 | 44968 | 4 |
1.545 | 4600 | 1 |
1.555 | 511 | 1 |
1.560 | 4136 | 2 |
Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
Featured News
SSM (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online